Frank Lichtenberg

Courtney C. Brown Professor of Business

Finance and Economics

Courtney C. Brown Professor of Business

Healthcare and Pharmaceutical Management Program

BA, University of Chicago, 1973; MA, University of Pennsylvania, 1976; PhD, 1982

Joined CBS in 1983

Download Curriculum Vitae (PDF)

Frank Lichtenberg

Office
504 Uris

Phone
212-854-4408

E-mail
frl1@columbia.edu

Fax
212-854-7647

Teaching and research interest

Frank R. Lichtenberg is Courtney C. Brown Professor of Business at the Columbia University Graduate School of Business; a Research Associate of the National Bureau of Economic Research; and a member of the CESifo Research Network. He received a BA with Honors in History from the University of Chicago and an MA and PhD in Economics from the University of Pennsylvania.

Mr. Lichtenberg previously taught at Harvard University, the University of Pennsylvania, and Ecole Polytechnique. He has served as an expert for the Federal Trade Commission, the U.S. Dept. of Justice, and state Attorneys General, and has testified before Congress. He has worked for several U.S. government agencies, including the Department of Justice, the Congressional Budget Office, and the Census Bureau, and been a visiting scholar at the Wissenschaftszentrum Berlin, the University of Munich, and elsewhere.

Some of Professor Lichtenberg’s research has examined how the introduction of new technology arising from research and development affects the productivity of companies, industries and nations. He has performed studies of the impact of pharmaceutical innovation on longevity, the effect of computers on productivity in business and government organizations, and the consequences of takeovers and leveraged buyouts for efficiency and employment. His articles have been published in numerous scholarly journals and in the popular press. His book Corporate Takeovers and Productivity has been published by MIT Press.

He was awarded the 1998 Schumpeter Prize for his paper, Pharmaceutical Innovation as a Process of Creative Destruction; the 2003 Milken Institute Award for Distinguished Economic Research for the paper, Pharmaceutical Knowledge-Capital Accumulation and Longevity; and Research!America’s 2010 Garfield Economic Impact Award for the paper, The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004.

He has been awarded research fellowships, grants, and contracts by the National Science Foundation, the World Health Organization, the National Institute of Standards and Technology, Merck and Co., the Fulbright Commission, the Brookings Institution, the Alfred P. Sloan Foundation, The German Marshall Fund, the American Enterprise Institute, and other organizations. He has served as a consultant to private organizations and government agencies including the Securities Industry Association, Pfizer, Inc., the Community Preservation Corporation, the RAND Corporation, the New York City Water Board, Touche Ross and Co., The Walt Disney Company, McGraw-Hill, and the National Pharmaceutical Council. He is an affiliate of the economics consulting firm Analysis Group.

Honors and awards

Chapters

Pharmaceutical Knowledge-Capital Accumulation and Longevity In Measuring Capital in the New Economy (2005)
Author(s): Frank Lichtenberg

More Information Download (PDF)

Journal articles

The contribution of pharmaceutical innovation to longevity growth in Germany and France, 2001–2007 In PharmacoEconomics (2012)
Author(s): Frank Lichtenberg

More Information Download (PDF)

Has Pharmaceutical Innovation Reduced Social Security Disability Growth? In International Journal of the Economics of Business (2011)
Author(s): Frank Lichtenberg

More Information Download (PDF)

Despite steep costs, payments for new cancer drugs make economic sense In Nature Medicine (2011)
Author(s): Frank Lichtenberg

More Information Download (PDF)

The quality of medical care, behavioral risk factors, and longevity growth In International Journal of Health Care Finance and Economics (2011)
Author(s): Frank Lichtenberg

More Information

What Are the Respective Roles of the Public and Private Sectors in Pharmaceutical Innovation? In Health Affairs (2011)
Author(s): Frank Lichtenberg, Bhaven Sampat

More Information

Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A Reexamination Using Data from the U.S. and Australia In Forum for Health Economics & Policy (2010)
Author(s): Frank Lichtenberg

More Information Download (PDF)

Pharmaceutical innovation and mortality in the United States, 1960–2000. A commentary on Schnittker and Karandinos In Social Science and Medicine (2010)
Author(s): Frank Lichtenberg

More Information

Pharmaceutical Price Discrimination and Social Welfare In Capitalism and Society (2010)
Author(s): Frank Lichtenberg

More Information Download (PDF)

The effect of drug vintage on survival: Micro evidence from Puerto Rico's Medicaid program In Advances in health economics and health services research (2010)
Author(s): Frank Lichtenberg

More Information Download (PDF)

Availability of New Drugs and Americans' Ability to Work In Journal of Occupational and Environmental Medicine (2005)
Author(s): Frank Lichtenberg

More Information Download (PDF)

The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982-2001 In International Journal of Health Care Finance and Economics (2005)
Author(s): Frank Lichtenberg

More Information Download (PDF)

The Effects of Medicare on Health Care Utilization and Outcomes In Frontiers in Health Policy Research (2002)
Author(s): Frank Lichtenberg

More Information Download (PDF)

Do (More and Better) Drugs Keep People Out of Hospitals? In American Economic Review (1996)
Author(s): Frank Lichtenberg

More Information Download (PDF)

The Private R and D Investment Response to Federal Design and Technical Competitions In American Economic Review (1988)
Author(s): Frank Lichtenberg

More Information Download (PDF)

The Comparative Advantage of Educated Workers in Implementing New Technology In Review of Economics and Statistics (1987)
Author(s): Ann Bartel, Frank Lichtenberg

More Information Download (PDF)

Books

Corporate Takeovers and Productivity (1992)
Author(s): Frank Lichtenberg

More Information

Working Papers

The Impact of Biomedical Knowledge Accumulation on Mortality: A Bibliometric Analysis of Cancer Data Working Paper No. 19593 (2013)
Author(s): Frank Lichtenberg

More Information Download (PDF)

The Impact of New (Orphan) Drug Approvals on Premature Mortality from Rare Diseases in the U.S. and France, 1999–2007 Working Paper (2011)
Author(s): Frank Lichtenberg

More Information Download (PDF)

Has medical innovation reduced cancer mortality? Working Paper No. 15880 (2010)
Author(s): Frank Lichtenberg

More Information Download (PDF)

Is Home Health Care a Substitute for Hospital Care? Working paper (2010)
Author(s): Frank Lichtenberg

More Information Download (PDF)

The impact of medical knowledge accumulation and diffusion on health: Evidence from Medline and other N.I.H. data Working paper (2010)
Author(s): Frank Lichtenberg

More Information Download (PDF)

The Quality of Medical Care, Behavioral Risk Factors, and Longevity Growth NBER Working Papers, Working Paper 15068 (2009)
Author(s): Frank Lichtenberg

More Information Download (PDF)

Benefits and Costs of Newer Drugs: An Update Working paper (2005)
Author(s): Frank Lichtenberg

More Information

Pharmaceutical-Embodied Technical Progress, Longevity, and Quality of Life: Drugs as 'Equipment for Your Health' Working paper (2005)
Author(s): Frank Lichtenberg, Suchin Virabhak

More Information

Sources of U.S. Longevity Increase, 1960-1997 Working paper (2005)
Author(s): Frank Lichtenberg

More Information

The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry Working paper (2005)
Author(s): Frank Lichtenberg

More Information

The Effect of Changes in Drug Utilization on Labor Supply and Per Capita Output Working paper (2005)
Author(s): Frank Lichtenberg

More Information

The Effect of Education on Medical Technology Adoption: Are the More Educated More Likely to Use New Drugs? Working paper (2005)
Author(s): Adriana Lleras-Muney, Frank Lichtenberg

More Information

The Expanding Pharmaceutical Arsenal in the War on Cancer NBR Working Paper 10328 (2005)
Author(s): Frank Lichtenberg

More Information Download (PDF)

The Impact of New Drug Launches on Longevity: From 52 Countries, 1982-2001 Working paper (2005)
Author(s): Frank Lichtenberg

More Information Download (PDF)

The Effect of New Drugs on Mortality from Rare Diseases and HIV NBER Working Paper 8677 (2002)
Author(s): Frank Lichtenberg

More Information

The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey NBER Working Paper 8147 (2001)
Author(s): Frank Lichtenberg

More Information

Pharmaceutical Innovation, Mortality Reduction, and Economic Growth NBER Working Paper W6569 (1998)
Author(s): Frank Lichtenberg

More Information

The Allocation of Publicly-Funded Biomedical Research NBER Working Paper 6601 (1998)
Author(s): Frank Lichtenberg

More Information

The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality NBER Working Paper No. W5418 (1996)
Author(s): Frank Lichtenberg

More Information